

Surrey & North West Sussex Area Prescribing Committee

<b>Policy Statement</b>	Apremilast (Otezla) for the treating active Psoriatic Arthritis (NICE TA433)
<b>Policy No:</b>	PCN 265-2017
<b>Date of Issue</b>	May 2017
<b>Review Date:</b>	<p><i>No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal.</i></p> <p><i>The recommendation made by the APC (formerly PCN) will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE)</i></p>
<p><b>Recommendations:</b>            The PCN recommends Apremilast as a treatment option for treating active psoriatic arthritis in line with NICE TA433 (22nd February 2017).</p> <p>Apremilast is a payment by results excluded drug which will be considered RED on the traffic light system.            The current psoriatic arthritis treatment pathway will be available on the prescribing advisory database.</p>	
<p><b>Key Considerations:</b></p> <ul style="list-style-type: none"> <li>NICE TA433 – Apremilast for the treating active Psoriatic Arthritis  <a href="https://www.nice.org.uk/guidance/ta433/resources/apremilast-for-treating-activepsoriatic-arthritis-pdf-82604722478533">https://www.nice.org.uk/guidance/ta433/resources/apremilast-for-treating-activepsoriatic-arthritis-pdf-82604722478533</a></li> </ul>	
<b>Date taken to Area Prescribing Committee</b>	3 <sup>rd</sup> May 2017
<b>Agreed by APC members</b>	12 <sup>th</sup> May 2017